

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

TWI PHARMACEUTICALS, INC.,
Petitioner,

v.

MERCK SERONO S.A.,
Patent Owner.

Case IPR2023-00049
U.S. Patent 7,713,947

**PATENT OWNER'S OPPOSITION TO PETITIONER'S
MOTION FOR ADDITIONAL DISCOVERY**

TABLE OF CONTENTS

I.	Statement of Material Facts.....	1
II.	Petitioner’s Requests should be denied because the requested materials are both privileged and protected work product.....	5
A.	Communications with counsel are privileged.....	5
B.	Dr. Bodor’s and Dr. Dandiker’s drafts and communications with counsel are protected work product	7
III.	Petitioner fails to establish its requests are in the interests of justice	8

TABLE OF AUTHORITIES

	Page(s)
CASES	
<i>ChemFree Corp. v. J. Walter, Inc.</i> , No. 04-3711, 2008 WL 5234252 (N.D. Ga. June 11, 2008).....	5
<i>Clemmons v. Acad. for Educ. Dev.</i> , No. 10- 911, 2013 WL 5994487 (D.D.C. Nov. 13, 2013)	7, 9
<i>Garmin Int’l, Inc. et al. v. Cuozzo Speed Techs. LLC</i> , IPR2012-00001, Paper No. 26 (March 5, 2013)	8
<i>In re Regents of Univ. of California</i> , 101 F.3d 1386 (Fed. Cir. 1996)	2
<i>In re Spalding Sports Worldwide, Inc.</i> , 1203 F.3d 800 (Fed. Cir. 2000)	6
<i>Murphy v. Kmart Corp.</i> , 259 F.R.D. 421 (D.S.D. 2009)	7–8
<i>Pevarello v. Lan</i> , 85 U.S.P.Q.2d 1771 (B.P.A.I. 2007).....	6, 7
<i>Shearing v. Iolab Corp.</i> , 975 F.2d 1541 (Fed. Cir. 1992)	6
<i>Siler v. EPA</i> , 908 F.3d 1291 (Fed. Cir. 2018).....	6
<i>Tennant Co. v. Oxygenator Water Techs. Inc.</i> , IPR2021-00625, Paper 30 (P.T.A.B. 2021)	10
<i>Twitter, Inc. v. Palo Alto Rsch. Ctr. Inc.</i> , IPR2021-01398, Paper 33 (P.T.A.B. Nov. 18, 2022)	6, 7, 8, 9

Petitioner improperly requests privileged communications between Drs. Bodor and Dandiker and their counsel, WilmerHale, including protected work product. Petitioner's request should be denied on this basis alone. Even if Petitioner were permitted to pierce both the declarants' privilege and related work product protections, Petitioner makes no attempt to demonstrate how its requested discovery would serve the interests of justice. On the contrary, Petitioner's requests should be denied as nothing more than a speculative fishing expedition.

I. Statement of Material Facts

Each of Petitioner's grounds in these IPRs relies on a single passage of the Bodor PCT. Pet. (Paper 1) 45-47. This passage of the Bodor PCT does not qualify as prior art, however, because the dosing regimen disclosed therein was made by the inventors of the challenged patents, not by Dr. Bodor or Dr. Dandiker.

Drs. Bodor and Dandiker are former employees of IVAX who partnered with Patent Owner's predecessor, Serono, to develop cladribine for treating MS. Ex. 2054, ¶18; Ex. 2055, ¶¶14-18. Drs. Bodor and Dandiker developed an oral formulation of cladribine. *Id.* Serono designed and ran clinical studies for treating MS with cladribine, including developing the regimens which Serono later patented. Ex. 2048, 2, 17-20; Ex. 2054, ¶13; Ex. 2055, ¶14. Even though "they

have no interest in the outcome of this matter whatsoever,”¹ Mot. (Paper 53) 6-7, Drs. Bodor and Dandiker each submitted a declaration confirming that they did not invent the cited dosing regimen; the Serono inventors did. Ex. 2054, ¶¶27-28; Ex. 2055, ¶¶25-29.

Each declarant sought WilmerHale’s legal advice regarding both preparation of their declarations, attesting that they did not invent any dosing regimen, and preparation for and representation at their depositions in these proceedings and related proceedings, *Hopewell Pharma Ventures, Inc. v. Merck Serono S.A.*, IPR2023-00480, IPR2023-00481, *Merck KGaA v. Hopewell Pharma Ventures, Inc.*, No. 22-1365 (Consolidated) (D. Del.). Dr. Bodor established an attorney-client relationship with WilmerHale as of October 18, 2023, and Dr. Dandiker

¹ Although Petitioner does not request them, communications between IVAX’s and Serono’s counsel regarding prosecution of the Bodor PCT, exchanged under a joint research agreement including developing a patent portfolio protecting cladribine for treating MS, Ex. 2048, are protected by common interest privilege. *In re Regents of Univ. of California*, 101 F.3d 1386, 1389 (Fed. Cir. 1996).

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.